EGFR and lung carcinoma: In the period 2013–2017, EGFR mutation testing in the Netherlands has transformed from a single-gene approach to the nationwide implementation of NGS using a multigene panel for predictive biomarker testing including EGFR according to the current Dutch national guideline for lung cancer [10].